gajananmnm
10+ Views

Artificial Cornea and Corneal Implant Market - Anticipated To Witness High Growth In The Near Future

According to the new market research report Artificial Cornea and Corneal Implant Market by Type (Human Cornea, Artificial Cornea), Transplant Type (Penetrating Keratoplasty, Endothelial Keratoplasty), Disease Indication, End Users (Hospitals, Specialty Clinics & ASCs) – Global Forecast to 2026″, published by MarketsandMarkets™, the global Artificial Cornea Implant Market is projected to reach USD 599 million by 2026 from USD 418 million in 2021, at a CAGR of 7.4% from 2021 to 2026.

Browse in-depth TOC on “Artificial Cornea and Corneal Implant Market”
102 – Tables
37 – Figures
156 – Pages


The Corneal Implant Market growth is largely driven by the The growing geriatric population and the rising prevalence of eye diseases are the major drivers for the artificial cornea and corneal implants market. The increasing prevalence of eye disorders and government initiatives to control visual impairment are further boosting the market growth.
The artificial cornea segment is projected to witness fastest growth during the forecast period

On the basis of type, the artificial cornea and corneal implants market is segmented into human cornea and artificial cornea. The artificial cornea segment is projected to witness fastest growth during the forecast period. An artificial corneal transplant, also known as keratoprosthesis (KPro), enables the restoration of vision in conditions wherein the cornea and the eye surface is affected or damaged. The scarcity of human eye donors has resulted in the development of innovative solutions such as artificial corneas. Additionally, individuals with a history of multiple previous graft failures, Stevens-Johnson syndrome, chemical burns, severe dry eyes, congenital aniridia, or limbal stem cell deficiency are indications for KPro. One of the commonly used keratoprosthesis is Boston Keratoprosthesis (Boston KPro). To date, over 15,000 Boston KPro have been implanted across the globe.

Penetrating keratoplasty segment accounted for the largest share of artificial corneal implant market in 2020.

On the basis of transplant type, the Artificial Cornea Implant Market is segmented into penetrating keratoplasty, endothelial keratoplasty, and other transplants (including anterior lamellar keratoplasty (ALK) and keratoprosthesis). In 2020, the penetrating keratoplasty segment accounted for the largest share of the global artificial cornea and corneal implants market. The large share of this segment can be attributed to the rising number of people suffering from eye disorders such as infectious keratitis and injury of the eyeball.

In 2020, Fuchs’ dystrophy segment accounted for the largest share of artificial cornea market

On the basis of disease indication, the corneal implants market is segmented into fungal keratitis, Fuchs’ dystrophy, keratoconus, and other diseases. In 2020, the Fuchs’ dystrophy segment accounted for the largest share of artificial cornea and corneal implant market. The rising incidence of the disease and the growing awareness among people regarding early disease diagnosis are the key factors driving the growth of this segment.

In 2020, hospitals segment accounted for the largest share of corneal implant market

Based on end users, the artificial cornea and corneal implants market is segmented into hospitals and specialty clinics and ambulatory surgery centers (ASCs). In 2020, hospitals segment accounted for the largest share of artificial corneal implant market. The rising prevalence of eye disorders, growth in the geriatric population, increasing awareness about the innovative artificial corneal technology, the willingness of patients to spend more on advanced treatments, and the growing number of hospitals in developing countries such as India, China, and Brazil are some of the key factors driving the growth of the artificial cornea and corneal implants market for hospitals.


Asia Pacific is expected to witness fastest growth during the forecast period of 2021–2026.

Geographically, the artificial cornea and corneal implant market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to witness highest CAGR during the forecast period of 2021–2026. The Asia Pacific forms the most lucrative region in the artificial cornea and corneal implants market, owing to the large population in countries such as China and India, rapid growth in the geriatric population, improving healthcare infrastructure, growing per capita income, and the rising focus of key market players on this region.

The prominent players in artificial cornea implant market are AJL Ophthalmic (Spain), CorneaGen Inc. (US), Addition Technology, Inc. (US), LinkoCare Life Sciences AB (Sweden), Presbia plc (Ireland), Mediphacos (Brazil), Aurolab (India), Cornea Biosciences (US), DIOPTEX GmbH (Austria), EyeYon Medical (Israel), Massachusetts Eye and Ear (US), Florida Lions Eye Bank (US), SightLife (US), Advancing Sight Network (US), San Diego Eye Bank (US) and L V Prasad Eye Institute (LVPEI, India).
gajananmnm
2 Likes
0 Shares
Comment
Suggested
Recent
Cards you may also be interested in
Jasa Pengiriman Bandung Simpang Tiga Redelong, Bener Meriah (0816267079)
Logistik Express Jasa Pengiriman Bandung Simpang Tiga Redelong, Bener Meriah merupakan jasa pengiriman barang dan cargo dari Bandung ke seluruh Indonesia. Logistik Express didukung oleh team operasional lapangan yang handal, customer service profesional, serta armada darat, laut, maupun udara yang memadai. Sehingga menjadikan Logistik Express sebagai jasa kirim yang aman sampai ke alamat tujuan. Bagi customer tidak perlu khawatir akan proses booking pengiriman yang rumit, karena cukup dengan menghubungi customer service maka barang kiriman anda langsung bisa di proses oleh team kami. Logistik Express juga dilengkapi dengan tracking website, sehingga pengiriman transparan dan mudah dilacak keberadaannya oleh customer. Jasa Kirim Ke  Simpang Tiga Redelong, Bener Meriah dari LogistikExpress.ID temukan harga terbaik untuk pengiriman Express di tempat kami yang telah berpengalaman dan pastinya barang anda aman sampai di tempat tujuan. Harga Tarif  hanya Rp12.000/Kg minimal pengiriman 100Kg Tarif Termurah Di Jasa Pengiriman Online Terbaru Dan Terupdate sampai 2021 di LogistikExpress.ID . LogistikExpress.ID adalah Jasa Pengiriman yang melayani pengiriman ke Seluruh wilayah Indonesia Layanan Customer Service & Order : +62816267079 Cek Tarif pengiriman dari Bandung lainnya : Ekspedisi Bandung simpang tiga redelong Ekspedisi Bandung sinabang Ekspedisi Bandung singaraja Ekspedisi Bandung singkawang Ekspedisi Bandung singkil Ekspedisi Bandung sinjai Ekspedisi Bandung sintang Ekspedisi Bandung sipirok Ekspedisi Bandung situbondo Ekspedisi Bandung slawi Ekspedisi Bandung sleman Ekspedisi Bandung soe Ekspedisi Bandung sofifi Ekspedisi Bandung solo Ekspedisi Bandung solok Ekspedisi Bandung soppeng Ekspedisi Bandung soreang Ekspedisi Bandung sorek Ekspedisi Bandung sorong Ekspedisi Bandung sorowako
The Future of Cell & Gene Therapy Manufacturing Services - Trends And Analysis
Growth in cell & gene therapy manufacturing services market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of cell & gene therapy manufacturing services market to a certain extent. According to GEP Worldwide, more than 1,200 clinical trials across the globe were disrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the suspension of patient enrolment. The impact varied due to changes in COVID-19 case volumes throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory disease, oncology, ID/anti-infectives, and cardiovascular disease were the worst-hit during this time. The trend suggests that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns on their investment in the long run and through collaborative R&D efforts. According to an EvaluatePharma report, the worldwide pharmaceutical R&D spending was valued at USD 136 billion in 2012; this increased to USD 186 billion in 2019. The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441 Most viral vectors are produced using adherent manufacturing, which is expensive to operate—a vial of 20 million cells can cost USD 20,000 to USD 30,000 to make. The cost of manufacturing for gene therapy can be between USD 500,000 and USD 1 million, excluding the costs for R&D, the costs to run crucial clinical trials, or the costs to build the commercial infrastructure necessary to provide access to patients. According to a 2020 PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number increased by 25% in 2020, with 362 cell & gene therapies in clinical development. In addition to this, according to data released by CGT Catapult, there were 154 ATMP clinical trials ongoing in the UK in 2020 compared to the 127 trials reported in 2019, indicating an increase of more than 20%.  
Protein Engineering : Future, Trends, And Scope
The growth of this market is majorly driven by factors such as the increasing investments in synthetic biology and the growing focus on protein-based drug development by pharmaceutical and biotechnology companies.  The rational protein design segment accounted for the largest share of the market in 2019. The large share of this segment can be attributed to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis.  The global market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global market, closely followed by Europe.  Factors such as the presence of well-established CROs, rising R&D expenditure, and the availability of the latest techniques and instruments for drug discovery research are responsible for the large share of the North American market. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=898  Monoclonal antibodies accounted for the largest share of the protein engineering market in 2019, majorly due to the high and growing demand for monoclonal antibodies for the treatment of cancer, neurological diseases, and infectious diseases.  The rational protein design segment accounted for the largest share of the market, majorly due to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis.  The protein engineering market is segmented into biopharmaceutical companies, contract research organizations, and academic research institutes. Biopharmaceutical companies use protein engineering products extensively in their drug discovery and development activities as these products help in designing models to develop a broad range of protein-based drugs. As a result, biopharmaceutical companies were the largest end-users in this market in 2019.  The major companies operating in the global protein engineering market include Thermo Fisher Scientific (US), Danaher Corporation (US), Agilent Technologies (US), and Bio-Rad Laboratories (US).  Market Research Developments: In 2019, Creative Biolabs (US) launched the cd25 monoclonal antibody. In 2019, Waters Corporation (US) launched Vanguard FIT Cartridge Technology. In 2019, Agilent Technologies (US) acquired BioTek Instruments (US), which helped the company to expand its expertise in cell analysis and establish its position in the immuno-oncology and immunotherapy markets. In 2019, Merck KGaA signed a license agreement with Amunix Pharmaceuticals, Inc. (US). Under this agreement, Amunix will gain the rights to develop therapeutics using the protease-triggered immune activator (ProTIA) technology platform.
Growth Opportunity, Regional Insights, Competitive Outlook For Microbial Identification
Growth in this market is largely driven by the rising incidence of infectious diseases and the increasing frequency of pandemics, technological advancements, increasing food safety concerns, and increasing government initiatives and funding to detect and control antimicrobial-resistant species.  COVID-19 Impact On The Global Microbial Identification Market According to a study conducted by ClinicalTrials.gov, to prevent screening shortages, an innovative PCR-free alternative strategy was developed based on the detection of specific protein signatures in human saliva by MALDI-TOF MS profiling. MALDI-TOF MS profiling is a method used in routine diagnostics by microbiology laboratories for the identification of microorganisms. MALDI-TOF MS profiling has been successfully used to classify individuals according to their infectious status based on the analysis of their saliva.  It is also used as a tool for the identification of respiratory viruses from cell culture supernatants. MALDI-TOF MS is one of the major technologies used in microbial identification. The COVID-19 pandemic has had a major impact on the US, China, India, as well as many major European countries. Since most of these countries are major manufacturers of the instruments and consumables used for microbial identification, the pandemic and nationwide lockdowns have caused a decline in the sales of these products.   Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10702182 Microbial identification is mainly used for human disease diagnosis. It delivers rapid and reliable results that help in the timely adoption of appropriate therapies. Microbial identification products can improve the management of infectious diseases, especially in areas with inadequate healthcare infrastructure. It is estimated that approximately 1,400 pathogens can cause human diseases.   Pathogenic bacteria alone cause about 350 million cases of foodborne diseases. About 48 million foodborne illnesses occur annually in the US alone, which leads to approximately 128,000 hospitalizations and 3,000 deaths every year. Poor water hygiene can cause 1.7 million deaths a year worldwide, and 9 out of 10 deaths occur in children. Most of these deaths, however, are observed in developing countries (NCBI). Over the years, there has been a significant increase in the prevalence of infectious diseases worldwide. According to the WHO, TB is one of the top 10 causes of death. A total of 1.5 million people died from TB in 2018 worldwide. Between 2000–2018, an estimated 58 million lives were saved through TB diagnosis and treatment. ccording to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2019, globally, 1.7 million people were newly infected with HIV, 38 million people are living with HIV, and 690,000 people died of AIDS-related illnesses. Furthermore, incidents such as the Zika epidemic (2016), Ebola epidemic (2014), H1N1 swine flu pandemic (2009), H5N1 Avian flu pandemic (2004), Severe Acute Respiratory Syndrome (SARS) pandemic (2003), and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic (2019–2020) have caused serious health concerns. They also lead to an increased demand for diagnostic products, including those for microbial identification. Thus, the high prevalence and incidence of different infectious diseases, coupled with the increasing frequency of pandemics, are driving growth in the microbial identification market.  Some of the leading players in the microbial identification market include bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Bruker Corporation (US), Shimadzu Corporation (Japan), QIAGEN NV (Netherlands), Avantor, Inc. (US), and Biolog, Inc. (US).  The phenotypic methods segment accounted for the largest share of the microbial identification market in 2019. The large share of this segment can be attributed to the wide usage of phenotypic methods for microbial identification across the healthcare, food & beverage, pharmaceutical, and environmental sectors
Fast, Affordable and Aesthetic 3D-printed Dental Restorations: Research News
The dental 3D printing medical devices market is primarily driven by factors such as the high incidence of dental caries and other dental diseases, rising demand for cosmetic dentistry, the growing adoption of dental 3D printers in hospitals and clinics, and rapid growth in the geriatric population.   In the optimistic scenario, it could be assumed that the COVID-19 pandemic would create a long-term positive impact on the overall dental 3D printing market. The dental 3D printing market was initially negatively impacted by the COVID-19 pandemic, as most dental offices, clinics, and laboratories were closed in many parts of the world due to lockdowns and quarantine restrictions in early 2020.   In an optimistic scenario, the need for smoother clinical workflows, faster turnaround times, and fewer dental appointments could boost the market growth. Dentists may be more likely to invest in technologies like CAD/CAM and dental 3D printing to reduce the time taken to deliver dental appliances and treatment, and patients may be more likely to opt for these solutions for the same reason.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258228239 Dental caries or tooth decay is a common ailment across all age groups, with the global incidence of decayed and missing teeth (DMT) increasing dramatically in recent years. According to the CDC, in 2019, 64.9% of adults aged above 18 years of age had a dental examination or dental cleaning procedure.   According to the American College of Prosthodontists, more than 36 million Americans are completely edentulous, and around 120 million Americans are missing at least one tooth. As dental implants, dental prosthetics, and other dental products manufactured by dental 3D printers find high use in the restoration of the dental structure, the high incidence of target diseases will play a key role in the growth of the dental 3D printing.    There is a very limited resource pool available for staff that is well-versed with 3D printing processes, which is further worsened by the rapid pace of evolution of the dental 3D printing market in terms of technology and materials. There is a dearth of training programs available for additive manufacturing and a wide gap between academia and practical applications in the industry that is difficult to bridge. The lack of a well-qualified workforce would restrain the overall adoption of dental 3D printing.  Key players in the Dental 3D Printing market: The prominent players in the global dental 3D printing market include Stratasys Ltd. (US), 3D Systems, Inc. (US), EnvisionTEC (Germany), DWS Systems SRL (Italy), Renishaw (UK), Formlabs (US), Prodways Group (France), SLM Solutions Group AG (Germany), Carbon, Inc. (US), Concept Laser (Germany), EOS GmbH Electro Optical Systems (Germany), Rapid Shape (Germany), Asiga (Australia), Roland DG (Japan), DENTSPLY Sirona, Inc. (US), SprintRay (US)
Jasa Pengiriman Bandung Raya, Simalungun (0816267079)
Bingung mencari Jasa Ekspedisi dan Pengiriman Barang yang terjangkau namun aman pengiriman sampai ke alamat tujuan ? Dapatkan kemudahan pengiriman dan tarif terjangkau di Logistik Express Jasa Pengiriman Bandung Raya, Simalungun Logistik Express Jasa Pengiriman Bandung Raya, Simalungun merupakan perusahaan yang menyediakan jasa pengiriman barang ke seluruh wilayah Indonesia. Kami menyediakan pengiriman melalui via darat, laut, maupun udara yang tentunya dengan tarif yang terjangkau dan pengiriman yang aman.Adapun beberapa pelayanan yang LOGISTIK EXPRESS yang dapat kami berikan kepada anda : Melayani Pickup Area Bandung dan Kab. Bandung sekitarnya. Pengiriman barang sampai ke alamat tujuan. Jasa Pengiriman ke Seluruh Wilayah Indonesia Layanan Muatan Cargo Besar Minimal 30Kg, 50kg, dan 100kg Seluruh Indonesia. Bisa Request Packing kiriman Kirim barang dengan Logistik Express Jasa Pengiriman Bandung Raya, Simalungun tentu murah tentu mudah. Dibantu dengan team operasional yang handal dan customer service profesional LOGISTIK EXPRESS siap mengirimkan barangmu sampai ke alamat tujuan dengan aman. Layanan Customer Service & Order : 0816267079 Cek layanan pengiriman dari Bandung lainnya : Ekspedisi Bandung simalungun Ekspedisi Bandung simpang ampek Ekspedisi Bandung simpang katis Ekspedisi Bandung simpang pematang Ekspedisi Bandung simpang rimba Ekspedisi Bandung simpang teritip Ekspedisi Bandung simpang tiga redelong Ekspedisi Bandung sinabang Ekspedisi Bandung singaraja Ekspedisi Bandung singkawang Ekspedisi Bandung singkil Ekspedisi Bandung sinjai Ekspedisi Bandung sintang Ekspedisi Bandung sipirok Ekspedisi Bandung situbondo
Get Top Preparation Tips from the Best Airforce Coaching
To join Air Force as an Airmen, a candidate has two options, Air Force X Group and Y Group. While taking a step for the preparation for Airmen, several queries come into the mind of a candidate. Through this post, we are trying to resolve all possible queries. Can I clear the Air Force X and Y group exam without joining coaching? A candidate can clear the institute exam institutes, but he will have to put a lot of effort into it. Good coaching institute carry lots of experience which can help you in clearing your exam easily. So, if you are also willing to join Air Force as an Airmen, we suggest you institute an exam join Air Force Coaching in Jaipur which can help you to clear your exam easily. How much time does it take to prepare for Air Force written exam? It totally depends on how well have you studied in class 11th and 12th and for the Y group in class 10th. If you have good command over it, you just need some guidance and you can clear it easily. But, if it is t the case just you need to focus on it, clarify the concept, and continue your preparation. What is the cut off marks for Air Force X and Y group? It keeps changing every year, depending on the number of candidates, the level of questions asked in the exam. Apart from the overall cut-off, candidates need to clear the individual cut-off for each subject. How much time it takes to come the results of written exam? Generally, 30 to 40 days’ time is taken by the Airmen Selection Board, but these days due to Covid and other reasons the time duration is not fixed. What about the second phase of the selection? As a candidate clears the written exam, he gets an email from the Airmen Selection Board about the Selection Centre and the date of reporting. On the reporting date three tests are conducted: Physical Fitness Test In this test, a 1.6 Km race is conducted with a time duration of 6 minutes and 30 secs. After that 10 Push Ups and 10 Sit Ups, tests are conducted. Those who successfully clear the first round only reach the second round. Adaptability Test-I This test involves objective-type questions in which 45 questions are asked. In these situations of different parameters are put forward before the candidates. The paper consists of 4 to 5 reasoning questions also. Adaptability Test-II This is the last test in which Group Discussion is organized. A Wing Commander ranked officer supervised the whole process. A sheet of paper is provided to each candidate in which the topic of some national of social importance is given. Candidates are required to read the topic, understand the grasp of it. After the paper is submitted to the Wing Commander, each candidate is asked to deliver on the topic after their self-introduction. After the last member of the group completes the process, the discussion on the topic starts and lasts for about 15 minutes. What about the medical process? After successful completion of the second phase, the candidates are provided the date of medical and venue. Candidates who successfully appear in the medical process are provided, Green Card. Those who have any issue regarding the medical process can apply for re-medical and clear it. What happens after the medical process? After the medical process, two lists come, the first is the PSL i.e., Provisional Select List and the Second is the Enrollment List. A candidate who comes under the Enrollment list receives the joining date and further documents required at the time of reporting at the training academy. Which is the best defence Academy in Jaipur There are many coaching academies in Jaipur or in India which provide guidance to clear Air Force X and Y Group exams. A candidate is advised to be rational while choosing one because a wrong choice can ruin his career. So, before you decide to join any coaching academy, check the parameters like availability of Physical Training Ground, Faculty Members, and Past selection record, etc.
Without Conviction Animal-Cruelty Case To End: Animal Treatment
The growth of the animal treatment market can be attributed to increasing government initiatives, which ensure maximum preventive healthcare for animals. A majority of the developed economies have norms that impel owners to have pet insurance.  By animal type, the horse's segment is expected to register the highest growth rate during the forecast period. Based on animal type, the animal treatment market is segmented into dogs, cats, horses, cattle, pigs, and poultry. The percentage of medical treatment received by horses is predicted to grow by 2024. In several countries, racehorses are considered to be of economic importance. Therefore, it becomes imperative for caretakers to provide maximum preventive as well as long-term veterinary care to equine species, as negligence pertaining to equine species may have an economic impact. On average, over 70-75% of the horses receive maximum preventive healthcare.  By treatment type, the veterinary care segment is expected to register the highest growth rate in the forecast period. Based on treatment type, the animal treatment market is segmented into no medicalization, basic medicalization, and veterinary care. Over the years, the demand for veterinary care services has increased. Veterinary clinics and hospitals in developed as well as developing countries are well-equipped with the necessary equipment for diagnosis and treatment. For instance, Banfield Hospital in the US is one of the most sophisticated hospitals that provides diagnostic tests for animals. North America is the largest market for animal treatment North America is the largest market in terms of the consumption of veterinary products. People are well versed with animal healthcare regulations, and hence high-quality care is provided to animals in this region.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180479252  However, the animal treatment market has become saturated in the US, as the number of veterinary visits has stabilized. On the contrary, the animal treatment rate in European countries has increased. The increasing standard of living and the growing number of veterinarians providing exceptional medical services to animals are the major factors driving the European animal treatment market. Prominent players in the animal treatment market are Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), Abaxis (US), Virbac SA (France), IDEXX Laboratories, Inc. (US), Neogen Corporation (US), and Heska Corporation (US).
Bioprocess Containers expected to register a CAGR of 26.3% during 2021-2026
Growth in the bioprocess containers market is mainly driven by factors such as the growing biologics market, affordability and sustainability of single-use bioprocess technologies, and rising biopharmaceutical R&D. Emerging countries and the patent expiry of biologics are expected to offer growth opportunities for players operating in the bioprocess containers market during the forecast period.  COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has since moved from being a regional crisis to a global pandemic.  Since most of the leading COVID-19 vaccine programs are using novel approaches, including mRNA, DNA vaccine, and vectors, these platforms are largely built on single-use technology. Most of the pandemic-related new facilities are largely engaging single-use systems due to their flexibility combined with high speed and much lower capital investment compared to traditional stainless steel equipment. The 2D bioprocess containers segment accounted for the largest share of the type segment in the bioprocess containers market in 2020. On the basis of type, the bioprocess containers market is segmented into 2D bioprocess containers, 3D bioprocess containers, and other containers and accessories. In 2020, the 2D bioprocess containers segment accounted for the largest share of the bioprocess containers market. 2D bioprocess containers are frequently used in cell harvesting and for the transportation of bulk drug products and bulk drug precursors.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832 The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the end user segment in the bioprocess containers market in 2020. On the basis of end user, the bioprocess containers market is segmented into pharmaceutical & biopharmaceutical companies, CROs & CMOs, and academic & research institutes. In 2020, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the bioprocess containers market. The demand for biopharmaceuticals among the senior population is increasing as the elderly are more prone to various diseases/disorders that can be treated using biologics.  The growth of single-use technologies can be attributed to the growing need for better, cheaper, and faster biologics production. Active development of individualized biologics and personalized medicines, including patient-specific cellular & gene therapies and therapeutic vaccines, demands high sterility and is therefore manufactured using single-use equipment and consumables.  In 2020, the US FDA approved 53 new medicines and therapeutic biologics (Source: US FDA). Growth in the biologics market is mainly driven by monoclonal antibodies and human insulin, which are among the leading contributors to the bioprocess containers market.  Additionally, the Centre for Biologics Evaluation and Research’s (CBER) (2021-25) strategic plan involves various schemes for boosting the growth of the biologics market. With increasing growth in the biologics market, the number of bioprocess containers needed for R&D and biologics manufacturing is also expected to increase in the coming years.  Request For Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=107645832 Extractables are compounds that can be extracted from source materials using appropriate solvents under vigorous laboratory conditions, while leachables are compounds present in drug products caused by leaching from containers, closures, and processing components. Therefore, leachables can be considered a subset of extractables.  Extractables and leachables are commonly associated with polymeric and elastomeric materials due to the use of additives to increase stability and aid in the formation of material components.  According to a survey conducted by BioPlan Associates in 2018, 73.3% of respondents agreed that leachables and extractables are major concerns that may limit the use of bioprocessing in the near future. As single-use assembly products are made of processed plastic materials, they often face the problem of contamination from the container due to leachables.  Some of the leading players operating in the bioprocess containers market are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US),  Danaher Corporation (US), and Merck Millipore (Germany).